AI-Driven Drug Discovery
These groundbreaking companies are redefining pharmaceutical research with artificial intelligence. Each has been carefully selected by our analysts for their potential to develop life-saving drugs faster and more efficiently than traditional methods allow.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Schrodinger Inc
SDGR
Current price
$19.70
This company's physics-based computational platform is central to its business, enabling the discovery of molecules for both drug development and mate...
This company's physics-based computational platform is central to its business, enabling the discovery of molecules for both drug development and materials science.
RECURSION PHARMACEUTICALS-A
RXRX
Current price
$5.53
It operates as a 'TechBio' company, using its proprietary Recursion OS platform to industrialize and accelerate drug discovery through large-scale dat...
It operates as a 'TechBio' company, using its proprietary Recursion OS platform to industrialize and accelerate drug discovery through large-scale data analysis.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
We're witnessing a technological revolution in medicine where AI dramatically cuts drug development time and costs. These companies aren't just adding AI to their toolkit—they've built their entire business models around computational platforms that design and test new drugs virtually, potentially saving years of laboratory work.
What You Need to Know
This is a high-growth, high-risk investment opportunity within healthcare innovation. Success hinges on AI-discovered drugs proving effective in clinical trials. These companies often partner with pharmaceutical giants, which can provide validation and revenue streams while their revolutionary technologies mature.
Why These Stocks
We've carefully selected companies that have made AI central to their drug discovery process, not just supplemental. Each firm has developed proprietary computational platforms designed to transform how new therapeutics are identified and developed, positioning them at the forefront of this industry-changing approach.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+344.62%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 344.62% over the next year.
Stocks Rated Buy by Analysts
14 of 15 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
The Drug Discovery Revolution
These companies are slashing the typical 10+ year drug development timeline by up to 75%. When their AI-discovered candidates succeed in clinical trials, stock prices often respond dramatically.
Partnership Potential
Major pharmaceutical companies are increasingly striking lucrative deals with these AI innovators. A single collaboration announcement can send share prices soaring as it validates their technology.
First-Mover Advantage
You're looking at the pioneers of a technological shift that's fundamentally changing a trillion-dollar industry. Early leaders in this space are building competitive moats through proprietary data and algorithms.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Consumer Caution: Value Prevails
A sharp drop in consumer sentiment, driven by persistent inflation fears, signals a potential shift in household spending. This theme focuses on companies poised to benefit as consumers prioritize essential goods and seek value.
Refining a New Opportunity: Venezuelan Crude Returns
Following a renewed U.S. license, Chevron has resumed oil shipments from Venezuela, creating a new supply of heavy crude for the market. This development presents a potential investment opportunity in U.S. refiners and logistics firms positioned to benefit from this strategic shift.
Consumer Strength: The Retail Rebound
A surprising surge in U.S. retail sales, driven by strong automotive and home furnishing purchases, signals continued consumer strength despite economic headwinds. This theme focuses on retailers and manufacturers in these key discretionary sectors that are benefiting from the robust consumer demand.
Frequently Asked Questions
Everything you need to know about the product and billing.